Abstract: A pharmaceutical composition is provided, which comprises an aqeous solution containing a mixture of di- and tri-sodium salts of echinochrome in an amount of 0.90 to 1.10 g/ml (Histochrome). It meets the requirements that apply to injectable formulations. Administration of Histochrome reduces by 57% the necrosis zone in patients with acute myocardial infarction, restores the contractility of the left ventricle, reduces the incidence of reperfusion-induced ventricular arrhythmias and exerts an antiarrhythmogenic effect. Histochrome suppresses the aggregation of erythrocytes and thrombocytes, produces a beneficial effect on the clinical course of the disease, reduces the incidence of complications and lethal outcomes in cases of acute myocardial infarction. It is well tolerated by patients.
Type:
Grant
Filed:
April 12, 2001
Date of Patent:
June 25, 2002
Assignee:
Tikhookeansky Institut Bioorganicheskoi Khimii
Dalnevostochnogo Otdeleniya Rossiiskoi Akademii Nauk
Abstract: A pharmaceutical composition is provided which comprises an isotonic solution of an 0.02% mixture of di- and trisodim salts of echinochrome (Histochrome). It meets the requirements that apply to injectable formulations. Histochrome administration to human patients normalizes metabolic processes and eliminates inflammation in the retina, vascular membrane and cornea of the eye, improves trophic functions, reduces edema and accelerates epithelization.
Type:
Grant
Filed:
April 12, 2001
Date of Patent:
May 7, 2002
Assignee:
Tikhookeansky Institut Bioorganicheskoi Khimii
Dalnevostochnogo Otdeleniya Rossiiskoi Akademii Nauk